MAS
REGN icon

Meeder Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Meeder Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
1,371
+121
+10% +$92.6K 0.04% 266
2025
Q4 		$965K Buy
1,250
+21
+2% +$14.3K 0.04% 280
2025
Q3 		$691K Buy
1,229
+42
+4% +$23.7K 0.03% 334
2025
Q2 		$623K Sell
1,187
-311
-21% -$174K 0.03% 336
2025
Q1 		$950K Sell
1,498
-210
-12% -$144K 0.06% 250
2024
Q4 		$1.22M Sell
1,708
-247
-13% -$207K 0.08% 201
2024
Q3 		$2.06M Buy
1,955
+86
+5% +$95.7K 0.13% 125
2024
Q2 		$1.96M Buy
1,869
+552
+42% +$535K 0.14% 123
2024
Q1 		$1.27M Buy
1,317
+52
+4% +$49.4K 0.13% 139
2023
Q4 		$1.11M Buy
1,265
+42
+3% +$34.6K 0.13% 138
2023
Q3 		$1.01M Sell
1,223
-276
-18% -$217K 0.13% 137
2023
Q2 		$1.08M Buy
1,499
+17
+1% +$13.1K 0.12% 150
2023
Q1 		$1.22M Buy
1,482
+177
+14% +$133K 0.14% 127
2022
Q4 		$942K Buy
+1,305
New +$963K 0.12% 165

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Meeder Advisory Services's REGN Position: Q1 2026 in Review

Meeder Advisory Services increased its Regeneron Pharmaceuticals (REGN) stake by 9.7% in Q1 2026, buying an estimated $92.6K and bringing the position to 1,371 shares worth $1.06M. The position accounts for 0.04% of the portfolio, ranked #266.

Meeder Advisory Services first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.06M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Meeder Advisory Services held 1,371 shares of Regeneron Pharmaceuticals worth $1.06M as of Q1 2026.
  • Meeder Advisory Services bought 121 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $92.6K.
  • Regeneron Pharmaceuticals made up 0.04% of Meeder Advisory Services's portfolio in Q1 2026, its #266 holding.
  • Meeder Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Meeder Advisory Services's Regeneron Pharmaceuticals position peaked at $2.06M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Meeder Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.